[The importance of the pharmaceutical form and the routes of administration of B-group vitamins for the efficacious treatment of neurosensorial hearing loss].
V F Antoniv, K V Efimochkina, T V Antoniv, V I Popadiuk, A U Kakupshev
Index: Vestn. Otorinolaringol. (2) , 57-60, (2012)
Full Text: HTML
Abstract
The objective of the present comparative study was to estimate the efficacy of the treatment of neurosensorial hearing loss (NSHL) with the use of milgamma, milgamma compositum, and vitamins B1 and B2 monotherapy. The best results were obtained after the treatment with milgamma and milgamma compositum. It is concluded that the use of these preparations for the combined treatment of neurosensorial hearing loss is pathogenetically justified since it permits to achieve the improvement of the functional state of the cochleovestibular nerve and the enhancement of patient compliance; moreover, it reduces the work load on the medical personnel.
Related Compounds
Related Articles:
2008-01-01
[BMC Pharmacol. 8 , 10, (2008)]
The detrimental effects of acute hyperglycemia on myocardial glucose uptake.
2014-06-06
[Life Sci. 105(1-2) , 31-42, (2014)]
The effect of benfotiamine on mu-opioid receptor mediated antinociception in experimental diabetes.
2014-03-01
[Exp. Clin. Endocrinol. Diabetes 122(3) , 173-8, (2014)]
Boosting the pentose phosphate pathway restores cardiac progenitor cell availability in diabetes.
2013-01-01
[Cardiovasc. Res. 97(1) , 55-65, (2013)]
Advanced glycation end-products inhibition improves endothelial dysfunction in rheumatoid arthritis.
2012-02-01
[Int. J. Rheum. Dis. 15(1) , 45-55, (2012)]